Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9526-9533
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9526
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9526
Table 4 Studies of sofosbuvir plus daclatasvir with or without ribavirin in recipients with hepatitis C recurrence after liver transplantation
| Authors | No. of patients | Patient characteristics | Antiviral Scheme (duration) | On treatment virological response (%) | SVR (%) |
| Leroy et al[39], (CUPILT study) | 21 | FCH: 100%, Treatment experience: 67% | SOF + Daclatasvir ± RBV (n = 13)SOF + RBV (n = 6)(24 wk) | 95 (12 wk) | - |
| Conti et al[40] | 55 | Fibrosis F3-F4: 33%,FCH: 7% | SOF + Daclatasvir(24 wk) | 85 (8 wk) | - |
- Citation: Cholongitas E, Pipili C, Papatheodoridis G. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol 2015; 21(32): 9526-9533
- URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9526.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9526